Abstract
Background: Hepatitis B (HB) infections are a global public health concern, which carry high morbidity and mortality. Immunization is the safe and effective intervention to prevent transmission. Currently, the Hepatitis B vaccine is given to children at two, four and six months of age in Sri Lanka. However, the capability of this regimen in providing long term protection up to adolescence and beyond remains a concern. The current study was conducted to assess the HB immune status of children, ten years after vaccination during infancy. Methods: Antibody status of 150 children who received HB vaccine at two, four and six months of age was assessed 10 years after the last dose of vaccination. Some of these children had received liquid monovalent HB vaccine, while others were vaccinated with the Hexavalent vaccine. Children with HB antibody levels below the protective level were given a booster dose of monovalent recombinant HB vaccine, and antibody levels were reassessed in one month. Results: At the initial assessment, 128 children (85%) had protective levels of antibodies. Type of vaccine and gender had no significant effect on the prevalence of HB antibody levels (p>0.05). All children who received the booster dose developed protective levels of antibodies. Conclusions: Most of the children immunized against HB during infancy maintain protective antibody levels at 10 years of age. Children with antibody levels below protective levels produced a rapid anamnestic response following a booster dose.
Highlights
Received 5 October 2021 and revised version accepted 8 January 2022
Hepatitis B is hyper-endemic in Western Pacific and South East Asian regions, with carrier rates ranging from 5-35%
We studied the immune status of children 10 years after vaccination with the recombinant Hepatitis B (HB) vaccine, administered either as the liquid monovalent vaccine or as the hexavalent vaccine during infancy
Summary
Http://sljol.info/index.php/SLJID Vol 12, No 1, April 2022. Hepatitis B (HB) infections are a global public health concern. Around 248 million individuals (3.6%) are positive for hepatitis B surface antigen.[1] Approximately 686,000 died worldwide from complications related to acute or chronic HB infections in 2013.2 inducing immunity against HB through immunization is a vital public health intervention. Located in a hyper-endemic region, Sri Lanka remains a low endemic country for Hepatitis B, with an estimated prevalence of less than 2%.5. Hepatitis B (HB) infections are a global public health concern, which carry high morbidity and mortality. The Hepatitis B vaccine is given to children at two, four and six months of age in Sri Lanka. The current study was conducted to assess the HB immune status of children, ten years after vaccination during infancy
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
